Clene’s (CLNN) cash and cash equivalents totaled $7.9 million as of September 30, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its cash and cash equivalents as of September 30, 2025, together with $1.2 million raised subsequent to September 30, 2025, will be sufficient to fund its operations into the second quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest
- Is CLNN a Buy, Before Earnings?
- Clene’s CNM-Au8: A Promising Candidate in ALS Treatment with Buy Rating from Justin Walsh
- Clene’s CNM-Au8: A Promising Game-Changer in ALS Treatment with Buy Rating from Justin Walsh
- Clene Enters Equity Distribution Agreement with Canaccord